Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8T7CG)

• Drug Name: tetronothiodin Drug Info
• Synonyms: Tetronothiodin; CHEMBL3576924; 139643-79-1; GTPL910; BDBM50088529; 3a,4,5,8,9,10,15,15a,18,19,23,23a-Dodecahydro-9,24-dihydroxy-4,17,18-trimethyl-alpha,21,23-trioxo-3H,21H-19a,22-metheno-1H-thieno(3,4-e)(1)benzoxacycloeicosin-3-acetic acid; 2-[(8Z,10E,15E)-13,26-dihydroxy-3,4,18-trimethyl-24,28-dioxo-27-oxa-21-thiatetracyclo[23.2.1.0^{1,6}.0^{19,23}]octacosa-4,8,10,15,25-pentaen-20-yl]-2-oxoacetic acid; 3H,21H-19a,22-Metheno-1H-thieno(3,4-e)(1)benzoxacycloeicosin-3-acetic acid, 3a,4,5,8,9,10,15,15a,18,19,23,23a-do

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 54695534
  CAS Number: CAS 139643-79-1
  TTD Drug ID: DM8T7CG

Molecule-Related Drug Atlas

Drug(s) Targeting Gastrin/cholecystokinin type B receptor (CCKBR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pentagastrin	DMRCLZB	Diagnostic imaging	N.A.	Approved	[3]
Ceruletide	DM2WE5K	Caerulein stimulated gastric and pancreatic secretion	5A4Y	Approved	[4]
GASTRAZOLE	DMO3ITF	Duodenal ulcer	DA63	Phase 3	[5]
Dexloxiglumide	DM52HUD	Pancreatic malfunction	DC30-DC3Z	Phase 2	[6]
Spiroglumide	DM7NJWY	Stomach disease	DA43-DA4Y	Phase 2	[7]
TT-223	DMCDMFP	Type-1 diabetes	5A10	Phase 2	[8]
Z 360	DM2M80G	Discovery agent	N.A.	Phase 2	[9]
S-0509	DM4KWEF	Ulcerative colitis	DD71	Phase 2	[10]
YF-476	DM54MAJ	Stomach ulcer	DA60.Z	Phase 2	[11]
Itriglumide	DM5UFRO	Anxiety disorder	6B00-6B0Z	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastrin/cholecystokinin type B receptor (CCKBR)	TTVFO0U	GASR_HUMAN	Antagonist	[2]

References

• [1] Tetronothiodin, a novel CCKB receptor ligand, antagonizes cholecystokinin-induced Ca2+ mobilization in a pituitary cell line. Eur J Pharmacol. 1992 Oct 6;221(1):99-105.
• [2] Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci Lett. 1993 Aug 6;158(1):1-4.
• [3] Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21.
• [4] Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.
• [5] Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 April 24; 94(8): 1107-1115.
• [6] Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
• [7] Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9.
• [8] The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.
• [9] Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gen... Biol Pharm Bull. 2010;33(2):216-22.
• [10] Selective action of a CCK-B/gastrin receptor antagonist, S-0509, on pentagastrin-, peptone meal- and beer-stimulated gastric acid secretion in dogs. Aliment Pharmacol Ther. 2000 Apr;14(4):479-88.
• [11] CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. Scand J Gastroenterol. 2004 Sep;39(9):886-90.
• [12] Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem. 2007; 7(12): 1211-1231.